XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities    
Net income $ 62.6 $ 843.7
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation and amortization 88.1 59.9
Equity-based compensation 122.4 85.1
Non-cash performance allocations and incentive fees, net 298.7 (89.8)
Non-cash principal investment income 2.7 (365.1)
Other non-cash amounts 19.9 (11.9)
Consolidated Funds related:    
Realized/unrealized (gain) loss on investments of Consolidated Funds (141.1) 248.1
Realized/unrealized (gain) loss from loans payable of Consolidated Funds 121.9 (227.4)
Purchases of investments by Consolidated Funds (1,718.3) (1,984.2)
Proceeds from sale and settlements of investments by Consolidated Funds 865.1 1,637.0
Non-cash interest income, net (15.9) (4.5)
Change in cash and cash equivalents held at Consolidated Funds (354.8) (82.9)
Change in other receivables held at Consolidated Funds (10.3) 10.6
Change in other liabilities held at Consolidated Funds 262.6 (31.2)
Purchases of investments (126.5) (456.8)
Proceeds from the sale of investments 137.2 287.1
Payments of contingent consideration (68.6) (5.7)
Changes in deferred taxes, net (91.6) 55.9
Change in due from affiliates and other receivables (4.4) (65.3)
Change in deposits and other (49.0) (7.1)
Change in accounts payable, accrued expenses and other liabilities (39.7) (67.2)
Change in accrued compensation and benefits (201.6) (372.1)
Change in due to affiliates (8.4) 2.8
Change in lease right-of-use assets and lease liabilities (5.0) (4.6)
Change in deferred revenue 5.0 (12.9)
Net cash used in operating activities (849.0) (558.5)
Cash flows from investing activities    
Purchases of corporate treasury investments (145.2) 0.0
Proceeds from corporate treasury investments 122.4 0.0
Purchases of fixed assets, net (32.5) (17.4)
Purchase of CBAM intangibles and investments, net 0.0 (618.4)
Net cash used in investing activities (55.3) (635.8)
Cash flows from financing activities    
Payments on CLO borrowings (4.5) (9.0)
Proceeds from CLO borrowings, net of financing costs 0.0 41.1
Net borrowings on loans payable of Consolidated Funds 876.1 405.9
Dividends to common stockholders (245.1) (207.1)
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)
Contributions from non-controlling interest holders 55.5 166.9
Distributions to non-controlling interest holders (34.1) (156.6)
Common shares issued for performance allocations 0.0 36.5
Common shares repurchased (160.8) (105.3)
Change in due to/from affiliates financing activities (10.3) (27.7)
Net cash provided by financing activities 408.0 75.9
Effect of foreign exchange rate changes 10.5 (46.9)
Decrease in cash, cash equivalents and restricted cash (485.8) (1,165.3)
Cash, cash equivalents and restricted cash, beginning of period 1,361.5 2,475.1
Cash, cash equivalents and restricted cash, end of period 875.7 1,309.8
Reconciliation of cash, cash equivalents and restricted cash, end of period:    
Cash and cash equivalents 870.3 1,308.9
Restricted cash 5.4 0.9
Total cash, cash equivalents and restricted cash, end of period 875.7 1,309.8
Cash and cash equivalents held at Consolidated Funds 536.4 230.7
Consolidated Operating Entities    
Cash flows from operating activities    
Net income 14.3 814.0
Adjustments to reconcile net income to net cash flows from operating activities:    
Depreciation and amortization 88.1 59.9
Equity-based compensation 122.4 85.1
Non-cash performance allocations and incentive fees, net 295.7 (94.6)
Other non-cash amounts 19.9 (11.9)
Consolidated Funds related:    
Purchases of investments (144.3) (470.3)
Proceeds from the sale of investments 141.6 298.2
Payments of contingent consideration (68.6) (5.7)
Changes in deferred taxes, net (91.6) 55.9
Change in due from affiliates and other receivables (4.4) (64.8)
Change in deposits and other (49.0) (7.1)
Change in accounts payable, accrued expenses and other liabilities (39.7) (67.2)
Change in accrued compensation and benefits (201.6) (372.1)
Change in due to affiliates (8.4) 2.8
Change in lease right-of-use assets and lease liabilities (5.0) (4.6)
Change in deferred revenue 5.0 (12.9)
Net cash used in operating activities 74.2 (113.7)
Cash flows from investing activities    
Purchases of corporate treasury investments (145.2) 0.0
Proceeds from corporate treasury investments 122.4 0.0
Purchases of fixed assets, net (32.5) (17.4)
Purchase of CBAM intangibles and investments, net 0.0 (618.4)
Net cash used in investing activities (55.3) (635.8)
Cash flows from financing activities    
Payments on CLO borrowings (4.5) (9.0)
Proceeds from CLO borrowings, net of financing costs 0.0 41.1
Dividends to common stockholders (245.1) (207.1)
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)
Contributions from non-controlling interest holders 5.2 4.4
Distributions to non-controlling interest holders (25.8) (36.6)
Common shares issued for performance allocations 0.0 36.5
Common shares repurchased (160.8) (105.3)
Change in due to/from affiliates financing activities (13.2) (27.8)
Net cash provided by financing activities (513.0) (372.6)
Effect of foreign exchange rate changes 8.3 (43.2)
Decrease in cash, cash equivalents and restricted cash (485.8) (1,165.3)
Cash, cash equivalents and restricted cash, beginning of period 1,361.5 2,475.1
Cash, cash equivalents and restricted cash, end of period 875.7 1,309.8
Supplemental non-cash disclosures    
Issuance of common shares related to the acquisition of CBAM 0.0 194.5
Reconciliation of cash, cash equivalents and restricted cash, end of period:    
Cash and cash equivalents 870.3 1,308.9
Restricted cash 5.4 0.9
Total cash, cash equivalents and restricted cash, end of period 875.7 1,309.8
Cash and cash equivalents held at Consolidated Funds $ 536.4 $ 230.7